Lemborexant

Lemborexant (INN) (code name E-2006) is a dual antagonist of the orexin OX1 and OX2 receptors which is under development by Eisai for the treatment of insomnia. In June 2016, Eisai initiated phase 3 clinical trials which are currently underway in the US, France, Germany, Italy, Japan, Poland, Spain and the UK, and are expected to extend to Canada. Lemborexant (INN) (code name E-2006) is a dual antagonist of the orexin OX1 and OX2 receptors which is under development by Eisai for the treatment of insomnia. In June 2016, Eisai initiated phase 3 clinical trials which are currently underway in the US, France, Germany, Italy, Japan, Poland, Spain and the UK, and are expected to extend to Canada.